T3D Therapeutics' Grant

T3D Therapeutics raised a round of funding on May 21, 2019. Investors include National Institute on Aging.

T3D Therapeutics is a privately-held pharmaceutical R&D company developing and commercializing T3D-959, potentially an optimal disease remedial therapeutic for the treatment of Alzheimer's Disease. Un…

Articles about T3D Therapeutics' Grant: